DOCKET NO.: Le A 31 923 C2 (BAYE-0050) **PATENT**

Application No.: 10/613,819 **Office Action Dated:** June 19, 2009

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1.-10. (Canceled)

11. (Previously Presented) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising administering to said animal a composition comprising: a therapeutically-effective amount of a first active ingredient selected from the group consisting of avermectin, 22,23-dihydroavermectin B₁, and milbemycin; and, a therapeutically-effective amount of a second active ingredient selected from the group consisting of agonists and antagonists of the nicotinergic acetylcholine receptors of insects.

- 12. (Previously Presented) The method according to claim 11 wherein said first active ingredient comprises an avermectin, a milbemycin, or both, and said second active ingredient comprises a chloronicotinyl, a chlorothiazolyl, or both.
- 13. (Previously Presented) The method according to claim 11 wherein said first active ingredient comprises moxidectin.
- 14. (Previously Presented) The method according to claim 13 wherein said second active ingredient comprises imidacloprid.
- 15. (Previously Presented) The method according to claim 11 wherein said first active ingredient comprises ivermectin.
- 16. (Previously Presented) The method according to claim 15 wherein said second active ingredient comprises imidacloprid.
- 17. (Previously Presented) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising:

identifying an animal having both an endoparasitic infection and an ectoparasitic infection; and,

administering to said identified animal a composition comprising

DOCKET NO.: Le A 31 923 C2 (BAYE-0050) PATENT

Application No.: 10/613,819

Office Action Dated: June 19, 2009

a therapeutically-effective amount of a first active ingredient selected from the group consisting of avermectin, 22,23-dihydroavermectin B₁, and milbemycin; and,

a therapeutically-effective amount of a second active ingredient selected from the group consisting of agonists and antagonists of the nicotinergic acetylcholine receptors of insects.

- The method according to claim 17 wherein said first active 18. (Previously Presented) ingredient comprises an avermectin, a milbemycin, or both, and said second active ingredient comprises a chloronicotinyl, a chlorothiazolyl, or both.
- 19. (Previously Presented) The method according to claim 17 wherein said first active ingredient comprises moxidectin.
- 20. (Previously Presented) The method according to claim 19 wherein said second active ingredient comprises imidacloprid.
- 21. (Previously Presented) The method according to claim 17 wherein said first active ingredient comprises ivermectin.
- 22. (Previously Presented) The method according to claim 21 wherein said second active ingredient comprises imidacloprid.
- 23. (New) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising administering to said animal a composition comprising: a therapeutically-effective amount of moxidectin; and, a therapeutically-effective amount of imidacloprid.
- 24. (New) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising:

identifying an animal having both an endoparasitic infection and an ectoparasitic infection; and,

administering to said identified animal a composition comprising

DOCKET NO.: Le A 31 923 C2 (BAYE-0050) **Application No.:** 10/613,819 **Office Action Dated:** June 19, 2009 **PATENT**

a therapeutically-effective amount of moxidectin; and,

a therapeutically-effective amount of imidacloprid.